Journal
NEUROSCIENCE
Volume 150, Issue 1, Pages 40-49Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuroscience.2007.08.021
Keywords
middle cerebral artery occlusion; MAPK; neuronal death; TAT-permeable peptide; neuroprotection
Categories
Ask authors/readers for more resources
The c-Jun N-terminal kinase (JNK) signaling pathway plays a critical role in ischemic brain injury. The D-retro-inverso form of c-Jun N-terminal kinase-inhibitor (D-JNKI1), a cell-permeable inhibitor of JNK, powerfully reduces neuronal death induced by permanent and transient ischemia, even when administered 6 h after the ischemic insult, offering a clinically relevant window. We investigated the JNK molecular cascade activation in rat cerebral ischemia and the effects of D-JNKI1 on this cascade. c-Jun activation starts after 3 In after ischemia and peaks at 6 h in the ischemic core and in the penumbra at I h and at 6 In respectively. The 6 h c-Jun activation peak correlates well with that of P-JNK. We also examined the activation of the two, direct JNK activators, MAP kinase kinase 4 (MKK4) and MAP kinase kinase 7 (MKK7). MKK4 showed the same time course as JNK in both core and penumbra, reaching peak activation at 6 h. MKK7 did not show any significant increase of phosphorylation in either core or penumbra. D-JNKI1 markedly prevented the increase of P-c-Jun in both core and penumbra and powerfully inhibited caspase-3 activation in the core. These results confirm that targeting the JNK cascade using the TAT cell-penetrating peptide offers a promising therapeutic approach for ischemia, raising hopes for human neuroprotection, and elucidates the molecular pathways leading to and following JNK activation. (c) 2007 IBRO. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available